• Moderna and Merck released five year follow up data from the phase 2b KEYNOTE-942/mRNA-4157-P201 trial of their individualized mRNA melanoma vaccine combined with Keytruda.
• The results showed a durable, clinically meaningful reduction in the risk of cancer recurrence or death compared with Keytruda alone.
• The data support Moderna’s push into oncology and rare diseases and may influence future standards of care in melanoma as phase 3 studies progress.

For investors watching NasdaqGS:MRNA, this update comes with the stock at $51.87 and a mixed return profile. The share price is up 31.8% over the past week, 60.6% over the past month, and 68.1% year to date. The three and five year returns show declines of 73.2% and 67.5% respectively. That backdrop helps frame how the market has been reassessing Moderna’s pipeline beyond COVID related products.

The long term melanoma data adds another piece to the story around mRNA in cancer treatment. As larger phase 3 studies progress and more oncology and rare disease readouts emerge, investors will likely focus on how consistently Moderna can translate this approach into clinically meaningful outcomes and potential future revenue streams.

Stay updated on the most important news stories for Moderna by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Moderna.

Investor Checklist: What This Means For Moderna

Quick Assessment

• ❌ Price vs Analyst Target: At US$51.87, the share price sits above the US$37.40 analyst consensus target.
• ❌ Simply Wall St Valuation: Valuation status is currently marked as unknown, so there is no clear undervalued signal here.
• ✅ Recent Momentum: The 30 day return of 60.6% shows strong recent momentum into this oncology update.

Check out Simply Wall St's in depth valuation analysis for Moderna.

Key Considerations

• 📊 The positive phase 2b melanoma data reinforces Moderna's effort to build a broader mRNA pipeline beyond COVID related products.
• 📊 Watch upcoming phase 3 melanoma results, revenue trends from US$2.2b in recent sales, and how the current P/E of 6.5 negative compares with the Biotechs average P/E of 19.9.
• ⚠️ One flagged risk is share price volatility, which can exaggerate reactions to both good and bad news.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Moderna analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.